Olfactory Neuroblastoma
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Olfactory Neuroblastoma

View Main Condition: Neuroblastoma

What is the definition of Olfactory Neuroblastoma?
Olfactory neuroblastoma is a rare cancer of the upper part of the nasal cavity called the cribiform plate, which is a bone deep in the skull between the eyes, and above the ethmoid sinuses. It accounts for about 5% of all cancers of the nasal cavity and paranasal sinuses. It develops in nerve tissue associated with the sense of smell (olfactory nerve). It can occur at any age, but typically is found in adulthood.
What are the alternative names for Olfactory Neuroblastoma?
  • Olfactory neuroblastoma
  • Esthesioneuroblastoma
Who are the top Olfactory Neuroblastoma Local Doctors?
Gary L. Gallia
Elite in Olfactory Neuroblastoma
Neurosurgery
Elite in Olfactory Neuroblastoma
Neurosurgery

Johns Hopkins Outpatient Center

601 North Caroline Street, Floor 5, Floor 5, 
Baltimore, MD 
Languages Spoken:
English
Offers Telehealth

Dr. Gary Gallia's specialty is endoscopic endonasal surgical approaches to skull base pathologies with a focus on neurosurgical oncology. He utilizes the latest techniques in preoperative imaging, computer-guided surgical navigation, intraoperative monitoring, and minimally invasive and Neuroendoscopy approaches in the management of patients with benign and malignant brain tumors, metastatic tumors to the brain, skull base neoplasms, and pituitary tumors. He is the director of the Neurosurgery Skull Base Center and surgical director of the Johns Hopkins Pituitary Center. Dr. Gary Gallia graduated summa cum laude from the Gibbons Scholar MD/PhD program at Jefferson Medical College and Thomas Jefferson University. He completed his general surgery internship at The Johns Hopkins Hospital where he was awarded surgical intern of the year. He then completed his neurological surgery residency and a postdoctoral fellowship in neuro-oncology at The Johns Hopkins Hospital. Following residency, he completed a minimally invasive and endoscopic neurosurgery fellowship with Dr. Charles Teo at the Prince of Wales Private Hospital and Sydney Children's Hospital in Sydney, Australia. Dr. Gallia is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Olfactory Neuroblastoma, Chordoma, Pituitary Tumor, Awake Craniotomy, and Craniectomy.

Nyall R. London
Elite in Olfactory Neuroblastoma
Otolaryngology
Elite in Olfactory Neuroblastoma
Otolaryngology

Johns Hopkins Health Care & Surgery Center — Bethesda

6420 Rockledge Drive, Suite 4920, Suite 4920, 
Bethesda, MD 
Languages Spoken:
English

Nyall London has a unique clinical practice focused on the care of patients with sinonasal and skull base cancers. As one of the few surgeons trained in both head and neck cancer surgery, as well as rhinology and skull base surgery, he offers patients comprehensive sinonasal tumor surgical care, including open and endoscopic approaches as well as neck dissection surgery. Dr. London has developed notable patient education events about the multidisciplinary and long-term care of patients with sinonasal malignancies. Additionally, he is an innovator of clinical trials for these rare tumors, with open clinical trial options available and multiple others in development. Internationally recognized for his expertise in the care of patients with sinonasal and skull base cancers, Dr. London was an associate editor for the first international consensus statement on sinonasal tumors, and was appointed president of the International Network for Sinonasal Cancer Research (2024–26). He directs a research laboratory at the National Cancer Institute/National Institutes of Health focused on therapeutic advances and mechanisms of sinonasal tumorigenesis. Dr. London has published more than 130 peer-reviewed research articles, reviews and book chapters, including co-first author publications in Nature, Nature Medicine, Science Translational Medicine and Nature Cell Biology. He earned his medical and doctoral degrees from the University of Utah, and completed his residency in otolaryngology–head and neck surgery at Johns Hopkins. He also accomplished a fellowship in open and endoscopic head and neck and skull base surgery at The Ohio State University, under the direction of Dr. Ricardo Carrau. Dr. London is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Olfactory Neuroblastoma, Sinus Cancer, Teratocarcinosarcoma, Endoscopy, and Craniectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Carl H. Snyderman
Elite in Olfactory Neuroblastoma
Otolaryngology
Elite in Olfactory Neuroblastoma
Otolaryngology

University Ear Nose And Throat Specialists

203 Lothrop Street, Suite 300, 
Pittsburgh, PA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Carl H. Snyderman, MD, is a professor in the department of otolaryngology at the University of Pittsburgh School of Medicine and codirector of the UPMC Center for Skull Base Surgery. He specializes in otolaryngology-head and neck surgery, and cranial base surgery. Dr. Snyderman is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Cerebrospinal Fluid Leak, Olfactory Neuroblastoma, Sinus Cancer, Endoscopy, and Nerve Decompression.

What are the latest Olfactory Neuroblastoma Clinical Trials?
A Natural History Study of Children and Adults With Olfactory Neuroblastoma

Background: Olfactory neuroblastoma (ONB) is a rare cancer. It grows from tissue in the upper part of the nose cavity, related to the sense of smell and can affect a person s sense of smell. Researchers want to better understand the health problems of people with ONB. This may help them design better treatment and supportive care studies.

Match to trials
Find the right clinical trials for you in under a minute
Get started
68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors.

Summary: The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and SSTR-positive systemic cancers metastatic to the brain, such as small cell carcinoma of the lung. The study indication is to determine the ...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center